

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2026**

All resolutions as set out in the Notice were duly passed by way of a poll at the AGM held on Thursday, 18 June 2026.

Reference is made to the circular (“**Circular**”) of New Ray Medicine International Holding Limited (“**Company**”) dated 28 April 2026 and the notice (“**Notice**”) of the annual general meeting (“**AGM**”) dated 28 April 2026 in relation to, among other matters, the proposals for the (i) grant of general mandates to repurchase and issue shares of the Company; (ii) re-election of the retiring directors of the Company; and (iii) proposed adoption of the Third Amended and Restated Bye-laws. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Circular.

The Board is pleased to announce that all resolutions as set out in the Notice were duly passed by the Shareholders by way of a poll at the AGM.

As at the date of the AGM, there were a total of 200,616,665 Shares in issue, and the Company did not hold any treasury shares (including any treasury shares held or deposited with the Central Clearing and Settlement System). To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, no Shareholder was required to abstain from voting on the resolutions proposed at the AGM. As such, there were a total of 200,616,665 Shares, representing 100% of the Shares in issue as at the date of the AGM, entitling the Shareholders to attend and vote on the resolutions proposed at the AGM. None of the Shareholders was entitled to attend and abstain from voting in favour of the resolutions proposed at the AGM according to Rule 13.40 of the Listing Rules. No Shareholder is required under the Listing Rules to abstain from voting. None of the Shareholders have stated their intention in the Circular to vote against the resolutions proposed or to abstain from voting at the AGM.

<b>ORDINARY RESOLUTIONS</b>		<b>Number of votes and percentage</b>	
		<b>For</b>	<b>Against</b>
1.	To receive and approve the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and the auditors of the Company for the year ended 31 December 2025.	48,668,580 (100.00%)	0 (0.00%)
2(a).	To re-elect Ms. Wang Qiuqin as an executive Director.	48,668,580 (100.00%)	0 (0.00%)
2(b).	To re-elect Mr. Sy Lai Yin, Sunny as an independent non-executive Director.	48,668,580 (100.00%)	0 (0.00%)
2(c).	To authorise the board of Directors to fix the respective Directors' remuneration.	48,668,580 (100.00%)	0 (0.00%)
3.	To re-appoint Moore CPA Limited as the auditors of the Company for the year ending 31 December 2026 and to authorise the board of Directors to fix its remuneration.	48,668,580 (100.00%)	0 (0.00%)
4.	To grant a general mandate to the Directors to allot, issue or otherwise deal with the Company's shares.	48,668,580 (100.00%)	0 (0.00%)
5.	To grant a general mandate to the Directors to repurchase the Company's shares.	48,668,580 (100.00%)	0 (0.00%)
6.	To extend the general mandate granted to the Directors to allot, issue or deal with the Company's shares by the number of shares repurchased.	48,668,580 (100.00%)	0 (0.00%)

SPECIAL RESOLUTION		Number of votes and percentage	
		For	Against
7.	To approve and adopt the New Bye-laws (as defined in the Circular) in substitution for, and to the exclusion of, the existing bye-laws of the Company and to authorise any Director or company secretary of the Company to do all things necessary to implement the adoption of the New Bye-laws.	48,668,580 (100.00%)	0 (0.00%)

*Notes:*

1. Full text of the resolutions are set out in the Notice.
2. The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the AGM in person, by authorised corporate representative or by proxy.

All Directors attended the AGM in person or via electronic means.

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 6, each of the resolutions was duly passed by the Shareholders as an ordinary resolution of the Company, and as no less than 75% of the votes was cast in favour of the resolution numbered 7, the resolution numbered 7 was duly passed by the Shareholders as a special resolution of the Company.

The Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Wang Qiuqin**  
*Chairman, Chief Executive Officer and Executive Director*

Hong Kong, 18 June 2026

*As at the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*